Servier drug for muscular dystrophy fails pivotal trial
Experimental drug sevasemten misses primary endpoint in large trial for rare muscular dystrophy.
(Michel Euler/AP)
French pharmaceutical company Servier announced on Nov. 3, 2026, that its experimental drug sevasemten failed to meet its primary endpoint in a Phase 3 clinical trial for the treatment of Becker muscular dystrophy. The study, known as the GRAND CANYON trial, showed no statistically significant benefit on the North Star Ambulatory Assessment.
The 18-month global study enrolled 175 adults with the rare, genetic, X-linked neuromuscular disorder, for which there are currently no approved treatments. According to the company, all secondary endpoints were also missed during the trial, although the drug maintained a favorable safety and tolerability profile.
The failure was unexpected, as it did not align with positive findings regarding muscle damage biomarkers observed in the earlier Phase 2 CANYON study. Servier is now conducting a comprehensive analysis of the trial data to evaluate the implications of these results for both Becker and Duchenne muscular dystrophy.
Servier acquired the muscular dystrophy business, including sevasemten, from Edgewise Therapeutics in a deal that closed on July 13, 2026. The transaction included a $1.55 billion upfront payment and up to $1.1 billion in potential regulatory and commercial milestones.
At the time of the acquisition, Servier President Olivier Laureau described the move as a strategic milestone in the company's goal to become a player in rare neurology. The Muscular Dystrophy Association has issued a statement regarding the results and intends to host an educational webinar featuring members of the Servier team to discuss the findings.